Combining PPI and KEGG pathway results, we infer that YFSJF may mainly treat NSCLC by targeting PIK3R1, PIK3CA, and AKT1 and regulating the PI3K/AKT pathway. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.